HK1221425A1 - 芋螺毒素(conotoxin)肽，其医药组合物和用途 - Google Patents

芋螺毒素(conotoxin)肽，其医药组合物和用途 Download PDF

Info

Publication number
HK1221425A1
HK1221425A1 HK16109735.3A HK16109735A HK1221425A1 HK 1221425 A1 HK1221425 A1 HK 1221425A1 HK 16109735 A HK16109735 A HK 16109735A HK 1221425 A1 HK1221425 A1 HK 1221425A1
Authority
HK
Hong Kong
Prior art keywords
conotoxin peptides
pharmaceutical compositions
analog conotoxin
peptides
contoxin
Prior art date
Application number
HK16109735.3A
Other languages
English (en)
Chinese (zh)
Inventor
J. Michael Mcintosh
Original Assignee
University Of Utah Research Foundation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University Of Utah Research Foundation filed Critical University Of Utah Research Foundation
Publication of HK1221425A1 publication Critical patent/HK1221425A1/zh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/43504—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Neurology (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Dermatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
HK16109735.3A 2013-05-31 2014-05-30 芋螺毒素(conotoxin)肽，其医药组合物和用途 HK1221425A1 (zh)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201361829633P 2013-05-31 2013-05-31
US201361829633P 2013-05-31
US201361843135P 2013-07-05 2013-07-05
US201361843135P 2013-07-05
PCT/US2014/040374 WO2014194284A1 (en) 2013-05-31 2014-05-30 Conotoxin peptides, pharmaceutical compositions and uses thereof

Publications (1)

Publication Number Publication Date
HK1221425A1 true HK1221425A1 (zh) 2017-06-02

Family

ID=51989449

Family Applications (1)

Application Number Title Priority Date Filing Date
HK16109735.3A HK1221425A1 (zh) 2013-05-31 2014-05-30 芋螺毒素(conotoxin)肽，其医药组合物和用途

Country Status (11)

Country Link
US (1) US10633417B2 (enExample)
EP (1) EP3003344B1 (enExample)
JP (1) JP6681826B2 (enExample)
KR (1) KR20160019469A (enExample)
CN (1) CN105377286B (enExample)
AU (1) AU2014273883B9 (enExample)
CA (1) CA2913993A1 (enExample)
HK (1) HK1221425A1 (enExample)
MX (1) MX367858B (enExample)
TW (1) TWI686205B (enExample)
WO (1) WO2014194284A1 (enExample)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11014970B2 (en) * 2014-11-07 2021-05-25 Kineta Chronic Pain, Llc Modifications and uses of conotoxin peptides
CN105985410B (zh) * 2015-02-16 2019-11-29 海南大学 芋螺肽、其药物组合物及用途
US10947274B1 (en) * 2018-05-01 2021-03-16 University Of Utah Research Foundation Synthetic analgesic peptides of RgIA analogs
US11612661B2 (en) 2019-01-04 2023-03-28 Kineta Chronic Pain, Llc Conotoxin peptide analogs and uses for the treatment of pain and inflammatory conditions
CN113493502B (zh) * 2020-04-01 2023-09-12 广西大学 α-芋螺毒素肽TxIE、其药物组合物及用途
US20230391838A1 (en) * 2020-06-03 2023-12-07 University Of Utah Research Foundation Conformationally-Constrained Alpha-RGIA Analogues
CN114805488B (zh) * 2021-01-29 2023-05-30 李威 一种靶向神经元烟碱型乙酰胆碱受体的新型多肽分子nAChR_BP及其应用
WO2022256066A1 (en) * 2021-06-03 2022-12-08 University Of Utah Research Foundation Selective penicillamine substitution enables development of a potent analgesic peptide that acts through a non-opioid based mechanism

Family Cites Families (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4352883A (en) 1979-03-28 1982-10-05 Damon Corporation Encapsulation of biological material
US4353888A (en) 1980-12-23 1982-10-12 Sefton Michael V Encapsulation of live animal cells
US4569967A (en) 1983-10-24 1986-02-11 The Salk Institute For Biological Studies Synthesis of N-substituted peptide amides
US4883666A (en) 1987-04-29 1989-11-28 Massachusetts Institute Of Technology Controlled drug delivery system for treatment of neural disorders
US5158881A (en) 1987-11-17 1992-10-27 Brown University Research Foundation Method and system for encapsulating cells in a tubular extrudate in separate cell compartments
US5283187A (en) 1987-11-17 1994-02-01 Brown University Research Foundation Cell culture-containing tubular capsule produced by co-extrusion
DE3829752A1 (de) 1988-09-01 1990-03-22 Akzo Gmbh Integrale asymmetrische polyaethersulfonmembran, verfahren zur herstellung und verwendung zur ultrafiltration und mikrofiltration
DE3829766A1 (de) 1988-09-01 1990-03-22 Akzo Gmbh Verfahren zur herstellung von membranen
US5082670A (en) 1988-12-15 1992-01-21 The Regents Of The University Of California Method of grafting genetically modified cells to treat defects, disease or damage or the central nervous system
US5084350A (en) 1990-02-16 1992-01-28 The Royal Institution For The Advance Of Learning (Mcgill University) Method for encapsulating biologically active material including cells
US5618531A (en) 1990-10-19 1997-04-08 New York University Method for increasing the viability of cells which are administered to the brain or spinal cord
EP0585368B1 (en) 1991-04-25 1997-08-06 Brown University Research Foundation Implantable biocompatible immunoisolatory vehicle for delivery of selected therapeutic products
US5854217A (en) 1992-09-28 1998-12-29 Bearsden Bio, Inc. Allosteric modulators of the NMDA receptor and their use in the treatment of CNS disorders and enhancement of CNS function
DE69423522T2 (de) 1993-04-27 2000-09-21 Cytotherapeutics, Inc. Membran aus einem acrylnitrilpolymer
EP0708670A4 (en) 1993-06-23 1998-07-01 Cytotherapeutics Inc METHOD AND APPARATUS FOR HERMETICALLY CLOSING IMPLANTABLE MEMBRANE ENCAPSULATING DEVICES
US5432155A (en) * 1993-06-29 1995-07-11 The Salk Institute For Biological Studies Conotoxins I
US5595972A (en) * 1993-06-29 1997-01-21 University Of Utah Research Foundation Conotoxin peptides
US5514774A (en) * 1993-06-29 1996-05-07 University Of Utah Research Foundation Conotoxin peptides
EP0802800B1 (en) 1993-08-12 2002-06-12 Neurotech S.A. Biocompatible immunoisolatory capsules containing genetically altered cells for the delivery of biologically active molecules
US5550050A (en) 1994-04-15 1996-08-27 Cytotherapeutics, Inc. Method for implanting encapsulated cells in a host
US5834029A (en) 1994-07-20 1998-11-10 Cytotherapeutics, Inc. Nerve guidance channel containing bioartificial three-dimensional hydrogel extracellular matrix derivatized with cell adhesive peptide fragment
US5833979A (en) 1994-07-20 1998-11-10 Cytotherapeutics, Inc. Methods and compositions of growth control for cells encapsulated within bioartificial organs
US5837234A (en) 1995-06-07 1998-11-17 Cytotherapeutics, Inc. Bioartificial organ containing cells encapsulated in a permselective polyether suflfone membrane
IN181898B (enExample) 1995-06-07 1998-10-24 Cytotherapeutics Inc
AU7204996A (en) 1995-10-02 1997-04-28 Cytotherapeutics, Inc. Method for treating amyotrophic lateral sclerosis
US5844077A (en) 1997-04-28 1998-12-01 Cytotherapeutics, Inc. Use of conantokins for producing analgesia or for neuroprotection
US5866682A (en) * 1997-05-15 1999-02-02 University Of Utah Research Foundation Conopeptides AuIA, AuIB and AuIC
WO1999033482A1 (en) * 1997-12-31 1999-07-08 University Of Utah Research Foundation Uses of alpha-conotoxin peptides
AUPP589598A0 (en) 1998-09-14 1998-10-08 University Of Queensland, The Novel peptides
AU778353B2 (en) * 1999-01-22 2004-12-02 Cognetix, Inc. Alpha-conotoxin peptides
US6767896B1 (en) * 1999-01-29 2004-07-27 Cognetix, Inc. Conotoxin peptides
US6797808B1 (en) * 1999-01-29 2004-09-28 University Of Utah Research Foundation α-conotoxin peptides
WO2000046371A1 (en) * 1999-02-04 2000-08-10 University Of Utah Research Foundation Tau-conotoxin peptides
CA2396529A1 (en) * 1999-12-30 2001-07-12 University Of Utah Research Foundation O-superfamily conotoxin peptides
US6767895B2 (en) * 2000-06-30 2004-07-27 Cognetix, Inc. I-superfamily conotoxins
JP2004537253A (ja) * 2000-07-21 2004-12-16 ユニバーシティ・オブ・ユタ・リサーチ・ファウンデーション ミュー−コノペプチド
WO2002064740A2 (en) * 2001-02-09 2002-08-22 Cognetix, Inc. Cone snail peptides
US7387997B2 (en) * 2004-11-09 2008-06-17 University Of Utah α-conotoxin MII analogues
CA2566832A1 (en) * 2006-04-13 2007-10-13 The University Of Queensland Cyclised alpha-conotoxin peptides
US9284358B2 (en) * 2006-07-18 2016-03-15 University Of Utah Research Foundation Conotoxin peptides
WO2008011006A2 (en) 2006-07-18 2008-01-24 University Of Utah Research Foundation Methods for treating pain and screening analgesic compounds
WO2011032233A1 (en) * 2009-09-21 2011-03-24 The University Of Queensland Novel omega conotoxin peptides
US9469674B2 (en) * 2012-08-07 2016-10-18 Hainan University α-conotoxin peptide, pharmaceutical composition and use thereof

Also Published As

Publication number Publication date
AU2014273883B2 (en) 2019-11-07
TW201503897A (zh) 2015-02-01
US10633417B2 (en) 2020-04-28
EP3003344A4 (en) 2016-12-28
AU2014273883B9 (en) 2020-06-18
CN105377286A (zh) 2016-03-02
JP2016520620A (ja) 2016-07-14
TWI686205B (zh) 2020-03-01
MX2015016492A (es) 2016-07-14
MX367858B (es) 2019-09-09
CA2913993A1 (en) 2014-12-04
AU2014273883A1 (en) 2015-12-17
JP6681826B2 (ja) 2020-04-15
US20160122388A1 (en) 2016-05-05
KR20160019469A (ko) 2016-02-19
CN105377286B (zh) 2021-07-02
EP3003344B1 (en) 2020-11-25
WO2014194284A1 (en) 2014-12-04
EP3003344A1 (en) 2016-04-13

Similar Documents

Publication Publication Date Title
HK1221425A1 (zh) 芋螺毒素(conotoxin)肽，其医药组合物和用途
HK1244201A1 (zh) 芋螺毒素(conotoxin)肽的修饰和用途
NZ630542A (en) Methods of treating a tauopathy
WO2015038796A3 (en) Secretion of heme-containing polypeptides
PH12015501648A1 (en) 2-aminopyrimidine derivatives for the treatment of viral infections
WO2015051030A8 (en) Stabilized polypeptides and uses thereof
WO2015010078A3 (en) Substituted 6,5-fused bicyclic heteroaryl compounds
MX2021011906A (es) Composiciones de liberacion retardada de linaclotida.
HK1217650A1 (zh) 用於治疗剧痛的组合物及方法
TN2018000180A1 (en) Polypeptides inhibiting cd40l
WO2011121576A3 (en) Immunogenic proteins and compositions for the treatment and prevention of streptococcus agalactiae
EP3625245A4 (en) PEPTIDE COMPOUNDS, CONJUGATE COMPOUNDS AND THEIR USES IN THE TREATMENT OF INFLAMMATORY DISEASES
HK1251481A1 (zh) 使用白介素-17(il-17)拮抗剂治疗放射学阴性中轴型脊柱关节炎的方法
PT3421038T (pt) Compostos de naftiridina, combinações médicas e sua utilização
MX2017006437A (es) Compuestos espiroisoquinolin-1,4'-piperidinicos con actividad multimodal contra el dolor.
IL241175A0 (en) A pharmaceutical preparation for the treatment of fungal infections
EP3280722B8 (en) Antimicrobial peptides and their use for the treatment of topical infections
WO2015031778A3 (en) Compositions and methods for the treatment or prevention of tuberculosis
AU2016298962A8 (en) Compounds and pharmaceutical composition associated with ubiquitination-proteasome system
WO2014152437A3 (en) Methods of use for an antimicrobial peptide
GB201518456D0 (en) Novel compounds and pharmaceutical compositions thereof for the treatment of inflammatory, autoimmune and/or proliferative diseases
WO2013192238A3 (en) Compositions and methods for treatment of diabetes
IL277632A (en) CDNF fragments from the carboxyl end, pharmaceutical compositions containing them and their uses
EP3399990A4 (en) THERAPEUTIC COMPOSITIONS WITH PEPTIDES AND USES THEREOF
WO2015073538A3 (en) Interaction with metalloenzymes